Page 1 | Page 2 | Page 3 | Page 4
Histogenesis-classification | Molecular-Genetic Aspects | Etiology-Pathogenesis | Genetic Tumor Syndromes | Diagnosis | Gliomas | Low-grade astrocytoma | Astrocytoma | Glioblastoma Multiforme | Pilocytic Astrocytoma | Oligodendroglioma | Ependymoma | Medulloblastoma | Meningioma | Schwannoma | Neurofibroma | Craniopharyngioma | Hemangioblastoma | Cerebral Lymphoma | The Effects of Brain Tumors

According to the SEER cancer statistics, close to a million and a half persons develop new cancers each year and over a half a million die from cancer. Compared to this, the number of new primary brain tumors (BT), about 18,000 or 1.4%, is relatively small. However, if one adds metastases from other cancers to the brain, the number of BT increases significantly. Primary BT claim close to 13,000 lives every year, 2.4% of all cancer deaths. The incidence of BT shows a peak in childhood followed by a decline till 25 years. After this, there is a continuous increase with advancing age. Cancer is second only to accidents as a cause of death in children 1 to 14 years old. It causes 10.5% of all deaths. In that age group, BT are the most frequent neoplasm after leukemia, accounting for about 18% of all cancers. The CNS is among the three leading sites of cancer mortality in the first three decades of life. It has been reported that the incidence of BT has been rising in recent years but much of this increase can be attributed to more accurate diagnosis, especially with MRI imaging. The only BT whose incidence has really increased is cerebral lymphoma.

As in all cancers, the tumor cells of BT display some features normal brain cells. This similarity may be obvious in the microscopic appearance and fine structure of tumor cells (especially in low-grade tumors) or revealed by their marker expression patterns, and is the basis of the classification of BT (see table below). This phenotypic-histologic classification has been in use for many decades and is also a histogenetic classification, i.e., it reflects our notions of the presumed cells of origin of BT.



A. Tumors of Glial Cells
Astrocytic tumors
Glioblastoma multiforme
Ependymoma – choroid plexus papilloma

B. Neuronal Tumors
Central neurocytoma

C. Embryonal Tumors





Pituitary adenoma


The term “glioma” refers to all glial tumors in general but is also used instead of astrocytoma.

metastatic carcinoma meningioma
Intra-axial tumor Extra-axial tumorThe terms “intra-axial” and “extra-axial,” used in radiological descriptions, mean “in brain or spinal cord tissue” and “extrinsic to brain” respectively. For instance, astrocytoma and oligodendroglioma are intra-axial; meningioma and Schwannoma are extra-axial. The term anaplasia describes the cellular atypia and loss of differentiation that are associated with malignant tumors.
In adults, metastatic BT outnumber primary ones but are less frequently subjected to biopsy or studied at autopsy. Among primary BT, the most common ones are meningioma, glioblastoma, and astrocytoma. In children, primary BT are more common than metastatic, and the most frequent among them are pilocytic astrocytoma and medulloblastoma. The most common tumors of the spinal cord are Schwannoma, meningioma, and ependymoma. The majority of BT in children arise in the cerebellum and brainstem (infratentorial). Most BT in adults arise in the cerebrum (supratentorial).

It had been assumed, until recently, that gliomas arise by transformation of normal glial cells. These cells were thought to be the only cells that had the capacity to divide, even though there is little evidence that they do so in the mature brain. This view is now being re-examined in the light of recent discoveries about neural stem cells (NSC), the multipotential precursors that give rise to neurons and glial cells. Until recently, NSCs were thought to be present mainly during fetal life, but it is now obvious that they also exist during post-natal life. They are more numerous and active during childhood, when the brain continues to develop, but are also found in the mature brain, especially around the ventricles, in the hippocampus, and in other locations.
It is likely that gliomas and other tumors of neuroglial cells arise from NSCs. NSCs are capable of proliferation and divergent differentiation. The genes that are expressed in these BT, including Nestin, EGFR, PTEN, Hedgehog, and others (see also below) are the same ones that are involved in neurogenesis and gliogenesis. This suggests that aberrant activation of developmental genetic programs in NSCs gives rise to BT. Such activation results in emergence of transformed cells with an enhanced ability to proliferate and migrate. The NSC origin explains the higher incidence of gliomas and medulloblastoma in children, the fact that some BT are composed of immature cells, the inclusion of neurons in some BT, and the presence of multiple cell types within the same tumor, such as oligoastrocytoma. The ultimate expression of multipotentiality is the development, in the brain, of teratomas, i.e., tumors containing derivatives of all 3 germ layers, similar to tumors arising in the gonads.

Some of the genes that are involved in neoplasia-oncogenes- promote cell growth and others –tumor suppressor genes-have the opposite action. Oncogenes code for growth factors, growth factor receptors, cytoplasmic signal transduction molecules, and nuclear transcription factors. When these proteins are inappropriately or excessively expressed (due to gene amplification, translocation, mutation, and other mechanisms), cells change their phenotypes and gain functions (such as moving through the extracellular matrix, inducing angiogenesis) that enhance their ability to survive, compared to their normal neighbors.

TP53 mutation
EGFR amplification
p16 alteration (chromosome 9p loss)
PTEN alteration (chromosome 10q loss)

OLIGODENDROGLIOMA: 1p and 19q loss
MENINGIOMA: Loss of 22q
SCHWANNOMA: Loss of 22q, mutations of the NF2 gene

The proteins of tumor suppressor genes, together with other catalytic and inhibitory factors, regulate the cell cycle and restrain cell proliferation. Loss of both copies of tumor suppressor genes (from mutation, chromosomal deletion, aberrant methylation, and other mechanisms) leads to unrestrained cell proliferation. Such mutation or deletion may result from acquired (environmental) damage of one allele, then the other. Iniduals who have one defective allele of a tumor suppressor gene in their germline tend to develop tumors at a young age, and this trait is transmitted to their children. The best known tumor suppressor genes are the retinoblastoma (Rb) gene on chromosome 13q, and p53 gene on 17p. Both these tumor suppressor genes are involved in the pathogenesis of BT. The table on the left shows some common genetic alterations in BT.

BT are initially derived from a single progenitor, but later, the genetic instability that is associated with rapid cell replication causes molecular and chromosomal changes to snowball, generating multiple tumor cell clones. This adds to the phenotypic heterogeneity and is reflected in the karyotypes and gene expression patterns of BT. Chromosome and molecular analysis are very important in the laboratory investigation of BT. Clues about the biology of BT revealed by such studies may be used to design chemotherapy that disrupts signaling pathways that cause BT to grow out of control.

Listed below are certain familial disorders that are associated with an increased risk of CNS tumors. Together, these and other familial tumor syndromes account for a small proportion (between 1% and 4%) of BT.
optic nerve glioma optic nerve glioma
NF1-Bilateral optic nerve astrocytoma Optic nerve astrocytoma
Von Recklinghausen neurofibromatosis (VRNF – Neurofibromatosis type 1-NF1), one of the most common genetic disorders, is autosomal dominant and is caused by mutations of a gene on chromosome 17q that encodes a protein called neurofibromin. Neurofibromin is involved in control of cell proliferation and acts as a tumor supressor. Patients with VRNF have a variety of tumors, including bilateral optic nerve astrocytomas, and plexiform neurofibromas and malignant peripheral nerve tumors of peripheral nerves. VRNF also causes café au lait spots of the skin, axillary and inguinal freckles, dysplasia of the sphenoid wing and other skeletal abnormalities, fibromuscular dysplasia of arteries, and other lesions.

Bilateral acoustic neurofibromatosis (BANF – Neurofibromatosis type 2-NF2) is an autosomal dominant condition characterized by acoustic and spinal schwannomas, meningiomas, ependymomas and lenticular opacities. It is due to inactivation of the NF2 gene on chromosome 22q. This gene encodes a structural protein, schwannomin or merlin, which has tumor suppressor activity.

tuberous sclerosis tuberous sclerosis
SEGA SEGATuberous Sclerosis is an autosomal dominant condition characterized by mental retardation, seizures, subependymal giant cell astrocytomas SEGA) and cortical hamartomas (tubers) of the CNS, skin abnormalities, and tumors and hamartomas of the heart, kidneys, and other organs. It has been linked to two genes, TS1 on 9q which encodes hamartin and TS2 on 16p which encodes tuberin. Hamartin and tuberin act together in regulating the cell cycle.
Von Hippel-Lindau Disease is an autosomal dominant disease, associated with hemangioblastomas of the cerebellum and retina, cysts of the liver and pancreas, pheochromocytomas, and tumors of the kidneys. It is linked to VHL, a tumor suppressor gene on chromosome 3p. The product of this gene is involved in mRNA transcription.

retinoblastoma retinoblastoma
Retinoblastoma Retinoblastoma
Retinoblastoma. Retinoblastoma is a malignant embryonal tumor of the eye similar to medulloblastoma. It is composed of “small blue cells”, which are frequently arranged in characteristic circular formations, the Flexner-Wintersteiner rosettes. Eighty five percent of retinoblastomas are sporadic. Fifteen percent are autosomal dominant and are often bilateral and multiple. Tumor development is due to deletion of the Rb tumor suppressor gene on chromosome 13q14. Familial tumors have a germline mutation resulting in one defective copy of the gene. Tumors develop when the remaining normal copy is altered due to a somatic mutation. The same principle is involved in the pathogenesis of other tumors.

Age: Embryonal tumors of the brain and other organs (cerebellar medulloblastoma, adrenal neuroblastoma, occur predominantly in children. Neurogenesis and neuronal migration in the cerebrum are largely completed by midgestation, but in the cerebellum they continue for the first year of life. Production of glial cells is very active in childhood. The brisk cell division that is associated with these processes gives the chance for new gene defects to arise and for inherited ones to be unmasked. The cerebellum is the most cellular part of the CNS (granular neurons outnumber all other neurons in the brain together) and takes the longest to develop. It is no coincidence that it is the most frequent site of BT in children.
Radiation: An increased incidence of BT, especially meningiomas, has been reported in patients who have received radiation to the head (even low-dose radation) for for a variety of reasons. Children with ALL who have been treated with craniospinal radiation are at high risk for developing meningiomas and gliomas. These tumors emerge many years after radiation has been given and appear to be on the rise.

Chemical Carcinogens: A variety of substances can induce mesenchymal and glial CNS tumors in animals by direct intracerebral inoculation and by oral and parenteral administration. The most potent neurocarcinogens in experimental animals are nitroso compounds (NOCs). NOCs are present in foods (cured meats, fish, vegetables), cosmetics, rubber products, even in beer and water, and are also synthesized in the mouth, stomach, and bladder by nitrosation of amines and amides in the diet. Given their ubiquitous nature, it is likely that they are also involved in human BT.

Immunosuppression: Cerebral lymphoma, usually B-cell, is frequent in patients with AIDS, renal transplants, congenital immunodeficiency syndromes, and other immunosupressed states. The finding of EBV DNA suggests that some of these tumors arise from EBV-infected B-cells.

Ki-67 stain
Ki67 immunostain
The laboratory evaluation of BT entails a pathological diagnosis, based on their gross, microscopic, immunohistochemial, and ultrastructural features, and an assessment of their clinical behavior (grade). Histological grading is based on cellularity, cellular and nuclear atypia (anaplasia), proliferative index, necrosis, and other features. The simplest proliferative index is a count of mitoses. More elaborate evaluations use antibodies against antigens such as Ki-67 that are expressed in actively proliferating cells, even if they are not in mitosis. Chromosome and molecular analysis also play an important role for diagnosis and for designing a biological approach to treatment. Pathologists will need to get into the habit of saving samples for such studies instead of using all the tissue for histologic analysis. The need for such samples is even more critical with the increasing use of stereotactic needle biopsies.